NABRIVA THERAPEUTICS AG's ticker is NBRVXXXX and the CUSIP is 62957M104. A total of 4 filers reported holding NABRIVA THERAPEUTICS AG in Q2 2017. The put-call ratio across all filers is - and the average weighting 3.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2017 | $139,000 | – | 11,593 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 4,021,559 | $48,259,000 | 14.20% |
| Omega Fund Management, LLC | 1,145,890 | $13,751,000 | 8.94% |
| Novo Holdings A/S | 2,326,544 | $27,919,000 | 2.97% |
| ACUTA CAPITAL PARTNERS, LLC | 677,710 | $8,133,000 | 1.93% |
| Almanack Investment Partners, LLC. | 155,817 | $1,870,000 | 1.40% |
| EcoR1 Capital, LLC | 264,773 | $3,177,000 | 0.80% |
| Boxer Capital, LLC | 176,710 | $2,121,000 | 0.46% |
| Rock Springs Capital Management LP | 525,000 | $6,300,000 | 0.36% |
| FT Options LLC | 19,848 | $238,000 | 0.31% |
| Orbimed Advisors | 1,677,940 | $20,135,000 | 0.23% |